Sierra Capital’s Novo Nordisk NVO Stock Holding History

Sierra Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,834	Closed	-$192K	–	442
2022 Q4	$192K	Buy	2,834 +2,800	+8,235%	+$164K	0.03%	186
2022 Q3	$2K	Hold	34	–	–	﹤0.01%	540
2022 Q2	$2K	Hold	34	–	–	﹤0.01%	609
2022 Q1	$2K	Buy	34 +6	+21%	+$308	﹤0.01%	687
2021 Q4	$2K	Sell	28 -10	-26%	-$542	﹤0.01%	702
2021 Q3	$2K	Hold	38	–	–	﹤0.01%	444
2021 Q2	$2K	Sell	38 -2	-5%	-$78	﹤0.01%	427
2021 Q1	$1K	Buy	+40	New	+$1.43K	﹤0.01%	422

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Sierra Capital's NVO Position: Q1 2023 in Review

Sierra Capital sold out of Novo Nordisk (NVO) in Q1 2023, closing a stake of 2,834 shares — an estimated $192K sold.

Sierra Capital first reported a position in NVO in Q1 2021 and held it in 8 quarters. The position peaked at $192K in Q4 2022. 1,146 funds tracked by Wall St. Rank hold NVO as of Q1 2023.

Sierra Capital reported no remaining Novo Nordisk position as of Q1 2023 after selling out during the quarter.
Sierra Capital sold 2,834 Novo Nordisk shares in Q1 2023, an estimated $192K.
Sierra Capital first reported a position in Novo Nordisk in Q1 2021 and held it in 8 quarters.
Sierra Capital's Novo Nordisk position peaked at $192K in Q4 2022.
1,146 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2023.

Based on Sierra Capital's 13F filing for Q1 2023, filed 1 May 2023.